Discovery of Potent and Selective c-Met Degraders for Hepatocellular Carcinoma Treatment

被引：2
|
作者：
Min, Wenjian [1 ,2 ,3 ]
Yang, Huanaoyu [1 ,2 ,3 ]
Wang, Dawei [1 ,2 ,3 ]
Chen, Chunling [1 ,2 ,3 ]
Wang, Yanyin [1 ,2 ,3 ]
Hou, Yi [1 ,2 ,3 ]
Zhu, Yasheng [1 ,2 ,3 ]
Sun, Chengliang [1 ,2 ,3 ]
Wang, Xiao [1 ,2 ,3 ]
Yuan, Kai [1 ,2 ,3 ]
Yang, Peng [1 ,2 ,3 ]
机构：
[1] China Pharmaceut Univ, State Key Lab Nat Med, Jiangsu Key Lab Drug Design & Optimizat, Nanjing 210009, Peoples R China
[2] China Pharmaceut Univ, Sch Pharm, Dept Med Chem, Nanjing 211198, Peoples R China
[3] China Pharmaceut Univ, Inst Innovat Drug Discovery & Dev, Nanjing 211198, Peoples R China
来源：
JOURNAL OF MEDICINAL CHEMISTRY | 2024年 / 67卷 / 14期
基金：
国家重点研发计划; 中国博士后科学基金; 中国国家自然科学基金;
关键词：
MEDIATED DEGRADATION; TARGET; CELL;
D O I：
10.1021/acs.jmedchem.4c01004
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
Targeting c-Met is a clinical trend for the precise treatment of HCC, but the potential issue of acquired drug resistance cannot be ignored. Targeted protein degradation technology has demonstrated promising prospects in disease treatment and overcoming drug resistance due to its special mechanism of action. In this study, we designed and synthesized two series of novel c-Met degraders and conducted a systematic biological evaluation of the optimal compound H11. H11 exhibited good c-Met degradation activity and anti-HCC activity. Importantly, H11 also demonstrated more potent inhibitory activity against Ba/F3-TPR-MET-D1228N and Ba/F3-TPR-MET-Y1230H cell lines than did tepotinib. In summary, H11 displayed potent anti-HCC activity as a degrader and may overcome resistance to type Ib inhibitors, making it a new therapeutic strategy for HCC with MET alterations.
引用
收藏
页码：12314 / 12330
页数：17
相关论文
共 50 条
  • [31] O-Linked Triazolotriazines: Potent and Selective c-Met Inhibitors
    Chen, Fang
    Wang, Ying
    Ai, Jing
    Zhan, Zhengsheng
    Lv, Yongcong
    Liang, Zhongjie
    Luo, Cheng
    Mei, Desheng
    Geng, Meiyu
    Duan, Wenhu
    CHEMMEDCHEM, 2012, 7 (07) : 1276 - 1285
  • [32] Identification and optimization of pyridazinones as potent and selective c-Met kinase inhibitors
    Dorsch, Dieter
    Schadt, Oliver
    Stieber, Frank
    Meyring, Michael
    Graedler, Ulrich
    Bladt, Friedhelm
    Friese-Hamim, Manja
    Knuehl, Christine
    Pehl, Ulrich
    Blaukat, Andree
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2015, 25 (07) : 1597 - 1602
  • [33] Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors (vol 19, pg 6307, 2009)
    Boezio, Alessandro A.
    Berry, Loren
    Albrecht, Brian K.
    Bauer, David
    Bellon, Steven F.
    Bode, Christiane
    Chen, April
    Choquette, Deborah
    Dussault, Isabelle
    Fang, Mei
    Hirai, Satoko
    Kaplan-Lefko, Paula
    Larrow, Jay F.
    Lin, Min-Hwa Jasmine
    Lohman, Julia
    Potashman, Michele H.
    Qu, Yusheng
    Rex, Karen
    Santostefano, Michael
    Shah, Kavita
    Shimanovich, Roman
    Springer, Stephanie K.
    Teffera, Yohannes
    Yang, Yajing
    Zhang, Yihong
    Harmange, Jean-Christophe
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (02) : 773 - 773
  • [34] MEDI 358-Discovery of pf-4254644 as a highly potent and exquisitely selective c-met inhibitor
    Shen, Hong
    Nambu, Mitchell
    Tran-Dube, Michelle
    Johnson, Catherine
    McTigue, Michele
    Parker, Max
    Yamazaki, Shinji
    Zou, Helen
    Christensen, James G.
    Cui, J. Jean
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2008, 236
  • [35] Discovery of Potent and Selective 8-Fluorotriazolopyridine c-Met Inhibitors (vol 58, pg 2417, 2015)
    Peterson, Emily A.
    Teffera, Yohannes
    Albrecht, Brian K.
    Bauer, David
    Bellon, Steven F.
    Boezio, Alessandro
    Boezio, Christiane
    Broome, Martin A.
    Choquette, Deborah
    Copeland, Katrina W.
    Dussault, Isabelle
    Lewis, Richard
    Lin, Min-Hwa Jasmine
    Lohman, Julia
    Liu, Jingzhou
    Potashman, Michele
    Rex, Karen
    Shimanovich, Roman
    Whittington, Douglas A.
    Vaida, Karina R.
    Harmange, Jean-Christophe
    JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (09) : 4087 - 4087
  • [36] Activation of the HGF/c-MET axis promotes lenvatinib resistance in hepatocellular carcinoma cells with high c-MET expression
    Rongdang Fu
    Shaotao Jiang
    Jieyuan Li
    Huanwei Chen
    Xiaohong Zhang
    Medical Oncology, 2020, 37
  • [37] Discovery of Potent and Selective G9a Degraders for the Treatment of Pancreatic Cancer
    Shi, Yunkai
    Shen, Qianqian
    Long, Ruikai
    Mao, Yiwen
    Tong, Shuaihang
    Yang, Yaxi
    Gao, Jing
    Zhou, Hu
    Chen, Yi
    Zhou, Bing
    JOURNAL OF MEDICINAL CHEMISTRY, 2024, 67 (15) : 13271 - 13285
  • [38] Activation of the HGF/c-MET axis promotes lenvatinib resistance in hepatocellular carcinoma cells with high c-MET expression
    Fu, Rongdang
    Jiang, Shaotao
    Li, Jieyuan
    Chen, Huanwei
    Zhang, Xiaohong
    MEDICAL ONCOLOGY, 2020, 37 (04)
  • [39] Discovery of 6-benzyloxyquinolines as c-Met selective kinase inhibitors
    Nishii, Hiroki
    Chiba, Takashi
    Morikami, Kenji
    Fukami, Takaaki A.
    Sakamoto, Hiroshi
    Ko, Kwangseok
    Koyano, Hiroshi
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (04) : 1405 - 1409
  • [40] Discovery of potent, selective and non-ATP competitive c-Met inhibitors: Daphnetin C-3 dimer derivatives
    Xu, Jimin
    Ai, Jing
    Liu, Sheng
    Geng, Meiyu
    Nan, Fajun
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2014, 247
12345